CO6680625A2 - Compuesto que actuan en multiples receptores de prostaglandina que dan una respuesta antinflamatoria general - Google Patents

Compuesto que actuan en multiples receptores de prostaglandina que dan una respuesta antinflamatoria general

Info

Publication number
CO6680625A2
CO6680625A2 CO13016511A CO13016511A CO6680625A2 CO 6680625 A2 CO6680625 A2 CO 6680625A2 CO 13016511 A CO13016511 A CO 13016511A CO 13016511 A CO13016511 A CO 13016511A CO 6680625 A2 CO6680625 A2 CO 6680625A2
Authority
CO
Colombia
Prior art keywords
compound
act
give
inflammatory response
hydrocarbyl
Prior art date
Application number
CO13016511A
Other languages
English (en)
Inventor
David F Woodward
Jose L Martos
Jenny W Wang
Hussi J Kangasmetsa
William Robert Carling
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CO6680625A2 publication Critical patent/CO6680625A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Reproductive Health (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)

Abstract

La presente invención proporciona un compuesto, que es un ácido1-[(2-{[(alquil o aril)metil]oxi}halo o haloalquil fenil sustituido)alquil]-5-hidrocarbil o hidrocarbil sustituido-1H-pirazol carboxílico o ácido alquenilcarboxílico o un hidrocarbil o hidrocarbil sulfonamida sustituido de dicho ácido carboxílico o dicho ácido alquenilcarboxílico, siempre que sin embargo dicho compuesto no sea un ácido 3-carhxílico, una sulfonamida de este, o un ácido 3-metilenilcarboxílico. El compuesto puede representarse por la siguiente fórmulaen donde R1, R2, R3, R4, R5, R6, X, W, X e Y son como se definió en la descripción. Los compuestos pueden administrarse para tratar enfermedades o afecciones mediadas por el receptor DP1, FP, EP1, TP y/o EP4.
CO13016511A 2010-07-01 2013-01-29 Compuesto que actuan en multiples receptores de prostaglandina que dan una respuesta antinflamatoria general CO6680625A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36075510P 2010-07-01 2010-07-01

Publications (1)

Publication Number Publication Date
CO6680625A2 true CO6680625A2 (es) 2013-05-31

Family

ID=44514984

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13016511A CO6680625A2 (es) 2010-07-01 2013-01-29 Compuesto que actuan en multiples receptores de prostaglandina que dan una respuesta antinflamatoria general

Country Status (17)

Country Link
US (3) US8492424B2 (es)
EP (1) EP2588459B1 (es)
JP (1) JP5922116B2 (es)
KR (1) KR20130141434A (es)
CN (1) CN103038219B (es)
AR (1) AR082073A1 (es)
AU (1) AU2011272716B2 (es)
BR (1) BR112013000065A2 (es)
CA (1) CA2804194C (es)
CL (1) CL2013000002A1 (es)
CO (1) CO6680625A2 (es)
ES (1) ES2625355T3 (es)
MX (1) MX2013000170A (es)
RU (1) RU2013102967A (es)
SG (1) SG186886A1 (es)
TW (1) TW201206891A (es)
WO (1) WO2012003414A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US9006450B2 (en) 2010-07-01 2015-04-14 Boehringer Ingelheim International Gmbh Compounds, pharmaceutical compositions and uses thereof
US8859606B2 (en) * 2010-07-01 2014-10-14 Allergan, Inc. Compounds act at multiple prostaglandin receptors giving a general anti-inflammatory response
US8969589B2 (en) * 2011-12-21 2015-03-03 Allergan, Inc. Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
US9090566B2 (en) 2011-12-27 2015-07-28 Allergan, Inc. Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
JP6132853B2 (ja) * 2011-12-27 2017-05-24 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 全身性抗炎症反応を提供する、複数のプロスタグランジン受容体で作用する化合物
EP2885008B1 (en) 2012-08-15 2018-11-07 University Of Virginia Patent Foundation Compositions and methods for treating peripheral arterial disease
ES2711356T3 (es) * 2013-01-21 2019-05-03 Allergan Inc Acción de compuestos en múltiples receptores de prostaglandina proporcionando una respuesta antinflamatoria general
CA2927981A1 (en) * 2013-10-31 2015-05-07 Allergan, Inc. 3-{1-[5-chloro-2-(2-ethylbutoxy)benzyl]-5-methyl-1h-pyrazol-3-yl}propanoic acid in crystalline form and methods for use thereof
CN106146400A (zh) * 2015-03-20 2016-11-23 四川大学 苄基-1h-吡唑、苄基-1h-吡咯衍生物及其制备方法和用途
US10462745B2 (en) 2016-01-15 2019-10-29 Google Llc Systems and methods for extending battery life by monitoring device activity
CN107723304A (zh) * 2016-08-10 2018-02-23 中国科学院上海生命科学研究院 Prkar2a在炎症消退中的应用
US11034669B2 (en) 2018-11-30 2021-06-15 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4826868A (en) * 1986-05-29 1989-05-02 Ortho Pharmaceutical Corporation 1,5-Diaryl-3-substituted pyrazoles pharmaceutical compositions and use
US7217725B2 (en) 2000-09-14 2007-05-15 Allergan, Inc. Prostaglandin D2 antagonist
US6511999B2 (en) 2000-09-14 2003-01-28 Allergan, Inc. Interheteroaryl 7-oxabicyclic [2.2.1]heptane oxazoles as prostaglandin F2α antagonists
US7273883B2 (en) 2000-09-14 2007-09-25 Allergan, Inc. Prostaglandin EP4 antagonist
US20070054951A1 (en) * 2003-05-20 2007-03-08 Lianhai Li Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin D2 antagonists
US20070060596A1 (en) 2003-10-24 2007-03-15 Giblin Gerard M P Heterocyclyl compounds
GB0508472D0 (en) * 2005-04-26 2005-06-01 Glaxo Group Ltd Compounds

Also Published As

Publication number Publication date
CA2804194C (en) 2019-03-05
CL2013000002A1 (es) 2013-05-31
AU2011272716B2 (en) 2016-05-19
JP5922116B2 (ja) 2016-05-24
RU2013102967A (ru) 2014-08-10
AU2011272716A1 (en) 2013-02-07
AR082073A1 (es) 2012-11-07
SG186886A1 (en) 2013-02-28
US8492424B2 (en) 2013-07-23
KR20130141434A (ko) 2013-12-26
MX2013000170A (es) 2013-05-28
TW201206891A (en) 2012-02-16
BR112013000065A2 (pt) 2019-09-24
ES2625355T3 (es) 2017-07-19
WO2012003414A1 (en) 2012-01-05
US20120165382A1 (en) 2012-06-28
EP2588459B1 (en) 2017-03-01
CA2804194A1 (en) 2012-01-05
US20130253028A1 (en) 2013-09-26
EP2588459A1 (en) 2013-05-08
US20140121258A1 (en) 2014-05-01
JP2013535424A (ja) 2013-09-12
CN103038219B (zh) 2016-08-24
CN103038219A (zh) 2013-04-10

Similar Documents

Publication Publication Date Title
CO6680625A2 (es) Compuesto que actuan en multiples receptores de prostaglandina que dan una respuesta antinflamatoria general
AR119698A2 (es) Compuesto amida n-urea sustituida derivado de aminoácido
WO2013096496A3 (en) Compounds acting at multiple prostaglandin receptors giving a general anti-inflammatory response
PE20141187A1 (es) Inhibidores sustituidos de aeitl-coa carboxilasa
EA201500173A1 (ru) Фунгицидные композиции
AR094262A1 (es) Compuestos antivirales para el tratamiento de la hepatitis c
BR112012030408A2 (pt) método de melhoramento de culturas
PE20142294A1 (es) Compuestos de indol e indazol que activan la ampk
PE20181039A1 (es) Metodo para preparar derivados de acido 3-(2-anilino-1-ciclohexil-1h-bencimidazol-5-il)propanoico sustituido
AR074511A1 (es) Proceso para la fabricacion de derivados del acido 5-metoximetilpiridin-2,3-dicarboxilico sustituido
AR072803A1 (es) Tetrahidrocinolinas como inhibidores de la 11- beta -hsd1 para la diabetes
AR117923A2 (es) Compuestos 4-amino-6-(4-fenilo sustituido)-picolinatos y 6-amino-2-(4-fenilo sustituido)-pirimidin-4-carboxilatos y composición que los comprende
RS53711B1 (en) MEDICINES FOR TREATMENT OF DISORDERS INCLUDING MODULATION OF RIANODINE RECEPTORS
RS52716B (en) HYDROBENZAMIDE DERIVATIVES AS HEAT SHOCK PROTEIN INHIBITORS HSP90
PE20142282A1 (es) Nuevos derivados de aril-quinolina
NZ594290A (en) Pyranose derived pesticidal compositions
PE20130236A1 (es) Composicion farmaceutica que comprende un derivado de amida o una sal farmaceuticamente aceptable del mismo
AR090172A1 (es) Proceso para la preparacion de carboxamidas
AR079662A1 (es) Indolil-piperidinil bencilaminas como inhibidores de beta-triptasa
CY1112079T1 (el) Νεες ενωσεις ως ανταγωνιστες των α1 υποδοχεων αδενοσινης
AR098965A1 (es) Derivados de sulfonamidas tricíclicas
EA201391268A1 (ru) СПОСОБ ПОЛУЧЕНИЯ 2-ЭТОКСИ-1-((2'-((ГИДРОКСИАМИНО)ИМИНОМЕТИЛ)ДИФЕНИЛ-4-ИЛ)МЕТИЛ)-1H-БЕНЗО[d]ИМИДАЗОЛ-7-КАРБОНОВОЙ КИСЛОТЫ И ЕЕ СЛОЖНЫХ ЭФИРОВ
MX2013002031A (es) Compuestos que actuan en multiples receptores de prostaglandina que proporcionan una respuesta antiinflamatoria general.
ECSP11011196A (es) Derivados de piperidina
CO6481003A2 (es) Compuesto de benzazepina